TLSA Tiziana Life Sciences PLC ADS

Tiziana Life Sciences Plc (the "Company") - Result of General Meeting

Tiziana Life Sciences Plc (the "Company") - Result of General Meeting
EN
02/10/2020

Underlying

TLSATiziana Life Sciences PLC ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tiziana Life Sciences PLC ADS

 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal For...

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoin...

June 13, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences to Present at the Bio International Convention

Tiziana Life Sciences to Present at the Bio International Convention NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its CEO, Ivor Elrifi, will be giving an oral presentation during the Bio International Convention in Boston, MA. Mr Elrifi’s presentation will cover the recent clinical findings of Tiziana’s lead drug candidate, i...

June 13, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Announces Interview Highlighting Intranasal Fora...

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced advancements in moderate Alzheimer's disease treatment, showcased in a recent feature on a national public radio station across the United States. The advancement...

May 23, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Na...

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the publication of a new study in the Journal of ‘Clinical Nuclear Medicine’ demonstrating that intranasal administration of foralumab significantly dampened...

May 15, 2025 1 EN
 PRESS RELEASE
Free
TLSA Tiziana Life Sc...

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Tiziana Life Sciences Announces Purchase of Shares by Chairman NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding to 43,252,143 common shares, which is 37.02% of issued share capital. About...

May 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch